Dynamics of the Pre-Powerstroke Myosin Lever Arm and the Effects of Omecamtiv Mecarbil
Abstract
:1. Introduction
2. Results
2.1. Omecamtiv Mecarbil Stiffened the Lever Arm and Converter Domain
2.2. Omecamtiv Mecarbil Altered Lever Arm Priming
2.3. Conformational Sampling and Interactions Made by Omecamtiv Mecarbil
2.4. Residue–Residue Interactions Varied with Lever Arm Orientation
3. Discussion
4. Materials and Methods
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Berg, J.S.; Powell, B.C.; Cheney, R.E. A Millennial Myosin Census. Mol. Biol. Cell 2001, 12, 780–794. [Google Scholar] [CrossRef]
- Sellers, J.R. Myosins: A Diverse Superfamily. Biochim. et Biophys. Acta (BBA)-Mol. Cell Res. 2000, 1496, 3–22. [Google Scholar] [CrossRef]
- Thompson, R.F.; Langford, G.M. Myosin Superfamily Evolutionary History. Anat. Rec. 2002, 268, 276–289. [Google Scholar] [CrossRef]
- Walklate, J.; Ujfalusi, Z.; Geeves, M.A.; Lindstedt, S.L.; Hoppeler, H.H. Myosin Isoforms and the Mechanochemical Cross-Bridge Cycle. J. Exp. Biol. 2016, 219, 168–174. [Google Scholar] [CrossRef]
- Morgan, B.P.; Muci, A.; Lu, P.-P.; Qian, X.; Tochimoto, T.; Smith, W.W.; Garard, M.; Kraynack, E.; Collibee, S.; Suehiro, I.; et al. Discovery of Omecamtiv Mecarbil the First, Selective, Small Molecule Activator of Cardiac Myosin. ACS Med. Chem. Lett. 2010, 1, 472–477. [Google Scholar] [CrossRef]
- Green, E.M.; Wakimoto, H.; Anderson, R.L.; Evanchik, M.J.; Gorham, J.M.; Harrison, B.C.; Henze, M.; Kawas, R.; Oslob, J.D.; Rodriguez, H.M.; et al. A Small-Molecule Inhibitor of Sarcomere Contractility Suppresses Hypertrophic Cardiomyopathy in Mice. Science 2016, 351, 617–621. [Google Scholar] [CrossRef]
- Chuang, C.; Collibee, S.; Ashcraft, L.; Wang, W.; Wal, M.V.; Wang, X.; Hwee, D.T.; Wu, Y.; Wang, J.; Chin, E.R.; et al. Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy. J. Med. Chem. 2021, 64, 14142–14152. [Google Scholar] [CrossRef]
- Voors, A.A.; Tamby, J.; Cleland, J.G.; Koren, M.; Forgosh, L.B.; Gupta, D.; Lund, L.H.; Camacho, A.; Karra, R.; Swart, H.P.; et al. Effects of Danicamtiv, a Novel Cardiac Myosin Activator, in Heart Failure with Reduced Ejection Fraction: Experimental Data and Clinical Results from a Phase 2a Trial. Eur. J. Heart Fail. 2020, 22, 1649–1658. [Google Scholar] [CrossRef] [PubMed]
- Olivotto, I.; Oreziak, A.; Barriales-Villa, R.; Abraham, T.P.; Masri, A.; Garcia-Pavia, P.; Saberi, S.; Lakdawala, N.K.; Wheeler, M.T.; Owens, A.; et al. Mavacamten for Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (EXPLORER-HCM): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. Lancet 2020, 396, 759–769. [Google Scholar] [CrossRef]
- Keam, S.J. Mavacamten: First Approval. Drugs 2022, 82, 1127–1135. [Google Scholar] [CrossRef]
- Maron, M.S.; Masri, A.; Nassif, M.E.; Barriales-Villa, R.; Arad, M.; Cardim, N.; Choudhury, L.; Claggett, B.; Coats, C.J.; Düngen, H.-D.; et al. Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy. N. Engl. J. Med. 2024, 390, 1849–1861. [Google Scholar] [CrossRef]
- Kooiker, K.B.; Mohran, S.; Turner, K.L.; Ma, W.; Martinson, A.; Flint, G.; Qi, L.; Gao, C.; Zheng, Y.; McMillen, T.S.; et al. Danicamtiv Increases Myosin Recruitment and Alters Cross-Bridge Cycling in Cardiac Muscle. Circ. Res. 2023, 133, 430–443. [Google Scholar] [CrossRef]
- Ráduly, A.P.; Sárkány, F.; Kovács, M.B.; Bernát, B.; Juhász, B.; Szilvássy, Z.; Porszász, R.; Horváth, B.; Szentandrássy, N.; Nánási, P.; et al. The Novel Cardiac Myosin Activator Danicamtiv Improves Cardiac Systolic Function at the Expense of Diastolic Dysfunction In Vitro and In Vivo: Implications for Clinical Applications. Int. J. Mol. Sci. 2022, 24, 446. [Google Scholar] [CrossRef]
- Teerlink, J.R.; Diaz, R.; Felker, G.M.; McMurray, J.J.V.; Metra, M.; Solomon, S.D.; Adams, K.F.; Anand, I.; Arias-Mendoza, A.; Biering-Sørensen, T.; et al. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. N. Engl. J. Med. 2020, 384, 105–116. [Google Scholar] [CrossRef]
- Felker, G.M.; Solomon, S.D.; Claggett, B.; Diaz, R.; McMurray, J.J.V.; Metra, M.; Anand, I.; Crespo-Leiro, M.G.; Dahlström, U.; Goncalvesova, E.; et al. Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure. JAMA Cardiol. 2022, 7, 26–34. [Google Scholar] [CrossRef]
- Kampourakis, T.; Zhang, X.; Sun, Y.; Irving, M. Omecamtiv Mercabil and Blebbistatin Modulate Cardiac Contractility by Perturbing the Regulatory State of the Myosin Filament. J. Physiol. 2018, 596, 31–46. [Google Scholar] [CrossRef]
- Malik, F.I.; Hartman, J.J.; Elias, K.A.; Morgan, B.P.; Rodriguez, H.; Brejc, K.; Anderson, R.L.; Sueoka, S.H.; Lee, K.H.; Finer, J.T.; et al. Cardiac Myosin Activation: A Potential Therapeutic Approach for Systolic Heart Failure. Science 2011, 331, 1439–1443. [Google Scholar] [CrossRef]
- Liu, Y.; White, H.D.; Belknap, B.; Winkelmann, D.A.; Forgacs, E. Omecamtiv Mecarbil Modulates the Kinetic and Motile Properties of Porcine β-Cardiac Myosin. Biochemistry 2015, 54, 1963–1975. [Google Scholar] [CrossRef] [PubMed]
- Winkelmann, D.A.; Forgacs, E.; Miller, M.T.; Stock, A.M. Structural Basis for Drug-Induced Allosteric Changes to Human β-Cardiac Myosin Motor Activity. Nat. Commun. 2015, 6, 7974. [Google Scholar] [CrossRef]
- Planelles-Herrero, V.J.; Hartman, J.J.; Robert-Paganin, J.; Malik, F.I.; Houdusse, A. Mechanistic and Structural Basis for Activation of Cardiac Myosin Force Production by Omecamtiv Mecarbil. Nat. Commun. 2017, 8, 190. [Google Scholar] [CrossRef] [PubMed]
- Auguin, D.; Robert-Paganin, J.; Réty, S.; Kikuti, C.; David, A.; Theumer, G.; Schmidt, A.W.; Knölker, H.-J.; Houdusse, A. Omecamtiv Mecarbil and Mavacamten Target the Same Myosin Pocket despite Opposite Effects in Heart Contraction. Nat. Commun. 2024, 15, 4885. [Google Scholar] [CrossRef]
- Hashem, S.; Tiberti, M.; Fornili, A. Allosteric Modulation of Cardiac Myosin Dynamics by Omecamtiv Mecarbil. PLoS Comput. Biol. 2017, 13, e1005826. [Google Scholar] [CrossRef]
- Antonovic, A.K.; Ochala, J.; Fornili, A. Comparative Study of Binding Pocket Structure and Dynamics in Cardiac and Skeletal Myosin. Biophys. J. 2023, 122, 54–62. [Google Scholar] [CrossRef]
- Uyeda, T.Q.; Abramson, P.D.; Spudich, J.A. The Neck Region of the Myosin Motor Domain Acts as a Lever Arm to Generate Movement. Proc. Natl. Acad. Sci. USA 1996, 93, 4459–4464. [Google Scholar] [CrossRef]
- Trivedi, D.V.; Muretta, J.M.; Swenson, A.M.; Davis, J.P.; Thomas, D.D.; Yengo, C.M. Direct Measurements of the Coordination of Lever Arm Swing and the Catalytic Cycle in Myosin V. Proc. Natl. Acad. Sci. USA 2015, 112, 14593–14598. [Google Scholar] [CrossRef]
- Ménétrey, J.; Llinas, P.; Mukherjea, M.; Sweeney, H.L.; Houdusse, A. The Structural Basis for the Large Powerstroke of Myosin VI. Cell 2007, 131, 300–308. [Google Scholar] [CrossRef]
- Sun, Y.; Goldman, Y.E. Lever-Arm Mechanics of Processive Myosins. Biophys. J. 2011, 101, 1–11. [Google Scholar] [CrossRef]
- Snoberger, A.; Barua, B.; Atherton, J.L.; Shuman, H.; Forgacs, E.; Goldman, Y.E.; Winkelmann, D.A.; Ostap, E.M. Myosin with Hypertrophic Cardiac Mutation R712L Has a Decreased Working Stroke Which Is Rescued by Omecamtiv Mecarbil. eLife 2021, 10, e63691. [Google Scholar] [CrossRef]
- Akter, F.; Ochala, J.; Fornili, A. Binding Pocket Dynamics along the Recovery Stroke of Human β-Cardiac Myosin. PLoS Comput. Biol. 2023, 19, e1011099. [Google Scholar] [CrossRef]
- Nandwani, N.; Bhowmik, D.; Childers, M.C.; Goluguri, R.R.; Dawood, A.; Regnier, M.; Spudich, J.A.; Ruppel, K.M. Hypertrophic Cardiomyopathy Mutations Y115H and E497D Disrupt the Folded-Back State of Human β-Cardiac Myosin Allosterically. bioRxiv 2024. [Google Scholar] [CrossRef]
- Klebl, D.P.; McMillan, S.N.; Risi, C.; Forgacs, E.; Virok, B.; Atherton, J.L.; Stofella, M.; Winkelmann, D.A.; Sobott, F.; Galkin, V.E.; et al. Swinging Lever Mechanism of Myosin Directly Demonstrated by Time-Resolved CryoEM. bioRxiv 2024. [Google Scholar] [CrossRef]
- Doran, M.H.; Rynkiewicz, M.J.; Rassici, D.; Bodt, S.M.L.; Barry, M.E.; Bullitt, E.; Yengo, C.M.; Moore, J.R.; Lehman, W. Conformational Changes Linked to ADP Release from Human Cardiac Myosin Bound to Actin-Tropomyosin. J. Gen. Physiol. 2023, 155, e202213267. [Google Scholar] [CrossRef]
- Kelley, L.A.; Gardner, S.P.; Sutcliffe, M.J. An Automated Approach for Clustering an Ensemble of NMR-Derived Protein Structures into Conformationally Related Subfamilies. Protein Eng. Des. Sel. 1996, 9, 1063–1065. [Google Scholar] [CrossRef] [PubMed]
- Laskowski, R.A.; Swindells, M.B. LigPlot+: Multiple Ligand–Protein Interaction Diagrams for Drug Discovery. J. Chem. Inf. Model. 2011, 51, 2778–2786. [Google Scholar] [CrossRef]
- Dominguez, R.; Freyzon, Y.; Trybus, K.M.; Cohen, C. Crystal Structure of a Vertebrate Smooth Muscle Myosin Motor Domain and Its Complex with the Essential Light Chain Visualization of the Pre–Power Stroke State. Cell 1998, 94, 559–571. [Google Scholar] [CrossRef]
- Spudich, J.A. How Molecular Motors Work. Nature 1994, 372, 515–518. [Google Scholar] [CrossRef]
- Lowey, S.; Saraswat, L.D.; Liu, H.; Volkmann, N.; Hanein, D. Evidence for an Interaction between the SH3 Domain and the N-Terminal Extension of the Essential Light Chain in Class II Myosins. J. Mol. Biol. 2007, 371, 902–913. [Google Scholar] [CrossRef] [PubMed]
- Landim-Vieira, M.; Childers, M.C.; Wacker, A.L.; Garcia, M.R.; He, H.; Singh, R.; Brundage, E.A.; Johnston, J.R.; Whitson, B.A.; Chase, P.B.; et al. Post-Translational Modification Patterns on β-Myosin Heavy Chain Are Altered in Ischemic and Nonischemic Human Hearts. eLife 2022, 11, e74919. [Google Scholar] [CrossRef]
- Sakthivel, S.; Joseph, P.K.; Tharakan, J.M.; Vosberg, H.; Rajamanickam, C. A Novel Missense Mutation (R712L) Adjacent to the “Active Thiol” Region of the Cardiac Β-myosin Heavy Chain Gene Causing Hypertrophic Cardiomyopathy in an Indian Family. Hum. Mutat. 2000, 15, 298–299. [Google Scholar] [CrossRef]
- Mohiddin, S.A.; Begley, D.A.; McLam, E.; Cardoso, J.-P.; Winkler, J.B.; Sellers, J.R.; Fananapazir, L. Utility of Genetic Screening in Hypertrophic Cardiomyopathy: Prevalence and Significance of Novel and Double (Homozygous and Heterozygous) -Myosin Mutations. Genet. Test. 2003, 7, 21–27. [Google Scholar] [CrossRef]
- Erdmann, J.; Daehmlow, S.; Wischke, S.; Senyuva, M.; Werner, U.; Raible, J.; Tanis, N.; Dyachenko, S.; Hummel, M.; Hetzer, R.; et al. Mutation Spectrum in a Large Cohort of Unrelated Consecutive Patients with Hypertrophic Cardiomyopathy. Clin. Genet. 2003, 64, 339–349. [Google Scholar] [CrossRef] [PubMed]
- Kimura, A.; Ito-Satoh, M.; Hayashi, T.; Takahashi, M.; Arimura, T. Molecular Etiology of Idiopathic Cardiomyopathy in Asian Populations. J. Cardiol. 2001, 37 (Suppl. S1), 139–146. [Google Scholar] [PubMed]
- Homburger, J.R.; Green, E.M.; Caleshu, C.; Sunitha, M.S.; Taylor, R.E.; Ruppel, K.M.; Metpally, R.P.R.; Colan, S.D.; Michels, M.; Day, S.M.; et al. Multidimensional Structure-Function Relationships in Human β-Cardiac Myosin from Population-Scale Genetic Variation. Proc. Natl. Acad. Sci. USA 2016, 113, 6701–6706. [Google Scholar] [CrossRef]
- Ingles, J.; Doolan, A.; Chiu, C.; Seidman, J.; Seidman, C.; Semsarian, C. Compound and Double Mutations in Patients with Hypertrophic Cardiomyopathy: Implications for Genetic Testing and Counselling. J. Med. Genet. 2005, 42, e59. [Google Scholar] [CrossRef]
- Chiou, K.-R.; Chu, C.-T.; Charng, M.-J. Detection of Mutations in Symptomatic Patients with Hypertrophic Cardiomyopathy in Taiwan. J. Cardiol. 2015, 65, 250–256. [Google Scholar] [CrossRef]
- Pan, S.; Caleshu, C.A.; Dunn, K.E.; Foti, M.J.; Moran, M.K.; Soyinka, O.; Ashley, E.A. Cardiac Structural and Sarcomere Genes Associated With Cardiomyopathy Exhibit Marked Intolerance of Genetic Variation. Circ. Cardiovasc. Genet. 2018, 5, 602–610. [Google Scholar] [CrossRef]
- Alfares, A.A.; Kelly, M.A.; McDermott, G.; Funke, B.H.; Lebo, M.S.; Baxter, S.B.; Shen, J.; McLaughlin, H.M.; Clark, E.H.; Babb, L.J.; et al. Results of Clinical Genetic Testing of 2,912 Probands with Hypertrophic Cardiomyopathy: Expanded Panels Offer Limited Additional Sensitivity. Genet. Med. 2015, 17, 880–888. [Google Scholar] [CrossRef] [PubMed]
- Arad, M.; Penas-Lado, M.; Monserrat, L.; Maron, B.J.; Sherrid, M.; Ho, C.Y.; Barr, S.; Karim, A.; Olson, T.M.; Kamisago, M.; et al. Gene Mutations in Apical Hypertrophic Cardiomyopathy. Circulation 2005, 112, 2805–2811. [Google Scholar] [CrossRef]
- Moric, E.; Mazurek, U.; Połońska, J.; Domal-Kwiatkowska, D.; Smolik, S.; Kozakiewicz, K.; Tendera, M.; Wilczok, T. Three Novel Mutations in Exon 21 Encoding Beta-Cardiac Myosin Heavy Chain. J. Appl. Genet. 2003, 44, 103–109. [Google Scholar]
- Driest, S.L.V.; Jaeger, M.A.; Ommen, S.R.; Will, M.L.; Gersh, B.J.; Tajik, A.J.; Ackerman, M.J. Comprehensive Analysis of the Beta-Myosin Heavy Chain Gene in 389 Unrelated Patients With Hypertrophic Cardiomyopathy. J. Am. Coll. Cardiol. 2004, 44, 602–610. [Google Scholar] [CrossRef]
- Lu, C.; Wu, W.; Liu, F.; Yang, K.; Li, J.; Liu, Y.; Wang, R.; Si, N.; Gao, P.; Liu, Y.; et al. Molecular Analysis of Inherited Cardiomyopathy Using next Generation Semiconductor Sequencing Technologies. J. Transl. Med. 2018, 16, 241. [Google Scholar] [CrossRef] [PubMed]
- Otsuka, H.; Arimura, T.; Abe, T.; Kawai, H.; Aizawa, Y.; Kubo, T.; Kitaoka, H.; Nakamura, H.; Nakamura, K.; Okamoto, H.; et al. Prevalence and Distribution of Sarcomeric Gene Mutations in Japanese Patients With Familial Hypertrophic Cardiomyopathy. Circ. J. 2012, 76, 453. [Google Scholar] [CrossRef]
- Harada, H.; Kimura, A.; Nishi, H.; Sasazuki, T.; Toshima, H. A Missense Mutation of Cardiac β-Myosin Heavy Chain Gene Linked to Familial Hypertrophic Cardiomyopathy in Affected Japanese Families. Biochem. Biophys. Res. Commun. 1993, 194, 791–798. [Google Scholar] [CrossRef] [PubMed]
- Millat, G.; Bouvagnet, P.; Chevalier, P.; Dauphin, C.; Jouk, P.S.; Costa, A.D.; Prieur, F.; Bresson, J.-L.; Faivre, L.; Eicher, J.-C.; et al. Prevalence and Spectrum of Mutations in a Cohort of 192 Unrelated Patients with Hypertrophic Cardiomyopathy. Eur. J. Med. Genet. 2010, 53, 261–267. [Google Scholar] [CrossRef] [PubMed]
- Webb, B.; Sali, A. Comparative Protein Structure Modeling Using MODELLER. Curr. Protoc. Protein Sci. 2016, 54, 5–6. [Google Scholar] [CrossRef] [PubMed]
- Anandakrishnan, R.; Aguilar, B.; Onufriev, A.V. H++ 3.0: Automating PK Prediction and the Preparation of Biomolecular Structures for Atomistic Molecular Modeling and Simulations. Nucleic Acids Res. 2012, 40, W537–W541. [Google Scholar] [CrossRef] [PubMed]
- Deacon, J.C.; Bloemink, M.J.; Rezavandi, H.; Geeves, M.A.; Leinwand, L.A. Identification of Functional Differences between Recombinant Human α and β Cardiac Myosin Motors. Cell. Mol. Life Sci. 2012, 69, 2261–2277. [Google Scholar] [CrossRef] [PubMed]
- Case, D.A.; Belfon, K.; Ben-Shalom, I.Y.; Brozell, S.R.; Cerutti, D.S.; Cheatham, T.E., III; Cruzeiro, V.W.D.; Darden, T.A.; Duke, R.E.; Giambasu, G.; et al. AMBER 2020; University of California: San Francisco, CA, USA, 2020. [Google Scholar]
- Maier, J.A.; Martinez, C.; Kasavajhala, K.; Wickstrom, L.; Hauser, K.E.; Simmerling, C. Ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from Ff99SB. J. Chem. Theory Comput. 2015, 11, 3696–3713. [Google Scholar] [CrossRef]
- Jorgensen, W.L.; Chandrasekhar, J.; Madura, J.D.; Impey, R.W.; Klein, M.L. Comparison of Simple Potential Functions for Simulating Liquid Water. J. Chem. Phys. 1983, 79, 926–935. [Google Scholar] [CrossRef]
- Li, P.; Song, L.F.; Merz, K.M. Parameterization of Highly Charged Metal Ions Using the 12-6-4 LJ-Type Nonbonded Model in Explicit Water. J. Phys. Chem. B 2014, 119, 883–895. [Google Scholar] [CrossRef]
- Li, P.; Song, L.F.; Merz, K.M. Systematic Parameterization of Monovalent Ions Employing the Nonbonded Model. J. Chem. Theory Comput. 2015, 11, 1645–1657. [Google Scholar] [CrossRef]
- Li, P.; Merz, K.M. Taking into Account the Ion-Induced Dipole Interaction in the Nonbonded Model of Ions. J. Chem. Theory Comput. 2013, 10, 289–297. [Google Scholar] [CrossRef] [PubMed]
- Kiani, F.A.; Fischer, S. Catalytic Strategy Used by the Myosin Motor to Hydrolyze ATP. Proc. Natl. Acad. Sci. USA 2014, 111, E2947–E2956. [Google Scholar] [CrossRef] [PubMed]
- He, X.; Man, V.H.; Yang, W.; Lee, T.-S.; Wang, J. A Fast and High-Quality Charge Model for the next Generation General AMBER Force Field. J. Chem. Phys. 2020, 153, 114502. [Google Scholar] [CrossRef] [PubMed]
- Neese, F.; Wennmohs, F.; Becker, U.; Riplinger, C. The ORCA Quantum Chemistry Program Package. J. Chem. Phys. 2020, 152, 224108. [Google Scholar] [CrossRef]
- Miyamoto, S.; Kollman, P.A. Settle: An Analytical Version of the SHAKE and RATTLE Algorithm for Rigid Water Models. J. Comput. Chem. 1992, 13, 952–962. [Google Scholar] [CrossRef]
- Roe, D.R.; Cheatham, T.E. PTRAJ and CPPTRAJ: Software for Processing and Analysis of Molecular Dynamics Trajectory Data. J. Chem. Theory Comput. 2013, 9, 3084–3095. [Google Scholar] [CrossRef]
- Martínez, L. Automatic Identification of Mobile and Rigid Substructures in Molecular Dynamics Simulations and Fractional Structural Fluctuation Analysis. PLoS ONE 2015, 10, e0119264. [Google Scholar] [CrossRef]
- Martínez, L.; Andreani, R.; Martínez, J.M. Convergent Algorithms for Protein Structural Alignment. BMC Bioinform. 2007, 8, 306. [Google Scholar] [CrossRef]
- Andreani, R.; Martínez, J.M.; Martínez, L.; Yano, F. Continuous Optimization Methods for Structure Alignments. Math. Program. 2008, 112, 93–124. [Google Scholar] [CrossRef]
- Pettersen, E.F.; Goddard, T.D.; Huang, C.C.; Couch, G.S.; Greenblatt, D.M.; Meng, E.C.; Ferrin, T.E. UCSF Chimera?A Visualization System for Exploratory Research and Analysis. J. Comput. Chem. 2004, 25, 1605–1612. [Google Scholar] [CrossRef]
System | Apo (OM-Free) | Holo (OM-Bound) | p-Value 8 | ||||||
---|---|---|---|---|---|---|---|---|---|
Replica | 1 | 2 | 3 | Avg. | 1 | 2 | 3 | Avg. | |
All Cα 1 | 5.1 | 4.6 | 5.4 | 5.0 | 3.7 | 4.8 | 3.7 | 4.1 | 0.08 |
Motor Domain 2 | 3.3 | 3.1 | 3.1 | 3.2 | 3.2 | 3.5 | 3.1 | 3.3 | 0.66 |
Converter 3 | 1.2 | 1.0 | 1.1 | 1.1 | 2.0 | 1.7 | 1.3 | 1.7 | 0.05 |
Tail 4 | 1.8 | 2.2 | 2.0 | 2.0 | 2.0 | 1.6 | 1.6 | 1.7 | 0.18 |
ELC 5 | 2.7 | 3.0 | 2.9 | 2.9 | 3.0 | 3.8 | 2.7 | 3.1 | 0.45 |
MDLOVO subset 6 | 1.0 | 1.1 | 1.2 | 1.1 | 1.2 | 1.3 | 1.3 | 1.3 | 0.04 |
MDLOVO all 7 | 7.3 | 6.3 | 7.6 | 7.1 | 4.3 | 5.3 | 4.5 | 4.7 | 0.01 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Childers, M.C.; Regnier, M. Dynamics of the Pre-Powerstroke Myosin Lever Arm and the Effects of Omecamtiv Mecarbil. Int. J. Mol. Sci. 2024, 25, 10425. https://doi.org/10.3390/ijms251910425
Childers MC, Regnier M. Dynamics of the Pre-Powerstroke Myosin Lever Arm and the Effects of Omecamtiv Mecarbil. International Journal of Molecular Sciences. 2024; 25(19):10425. https://doi.org/10.3390/ijms251910425
Chicago/Turabian StyleChilders, Matthew Carter, and Michael Regnier. 2024. "Dynamics of the Pre-Powerstroke Myosin Lever Arm and the Effects of Omecamtiv Mecarbil" International Journal of Molecular Sciences 25, no. 19: 10425. https://doi.org/10.3390/ijms251910425